How many insider trades does FilingIQ track for ENGN?

FilingIQ tracks 35 Form 4 insider transactions for ENGN (enGene Therapeutics Inc.), covering filings from Nov 2, 2023 onwards. 1 of those are dated within the last 90 days.

Are ENGN insiders net buyers or net sellers?

Across the full Form 4 history for ENGN, 16 transactions (46%) were open-market purchases and 3 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ENGN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.

What sector is ENGN in?

enGene Therapeutics Inc. (ENGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $652.43M.

ENGN insider trading

Healthcare

enGene Therapeutics Inc.: insider trade history from SEC Form 4 filings.

Total Form 4 trades

Last 90 days

Buys / sells

46% / 9%

Market cap

$652.43M

About enGene Therapeutics Inc.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGene Holdings Inc. is based in Montreal, Canada.

Company website: www.engene.com

ENGN insider activity at a glance

FilingIQ tracks 35 insider transactions for ENGN in filings since Nov 2, 2023. The most recent transaction is dated Sep 22, 2026.

Across the full history, 16 open-market purchases and 3 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ENGN insider trades is 50.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ENGN trades on FilingIQ Raw filings on SEC EDGAR

Latest ENGN Form 4 filings

Grossman William Interim Chief Medical Officer

Grossman William Interim Chief Medical Officer

A Jun 17, 2026

HASTINGS PAUL J

A Jun 17, 2026

Heffernan Michael Thomas

CHEUNG ANTHONY TZEYEW Chief Scientific Officer

A Feb 3, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 772

UNITED THERAPEUTICS Corp

BLLN 164

BillionToOne, Inc.

TMO 130

THERMO FISHER SCIENTIFIC INC.

ATTO 123

Attovia Therapeutics, Inc.

CASTLE BIOSCIENCES INC

Frequently asked

How many insider trades does FilingIQ track for ENGN?: FilingIQ tracks 35 Form 4 insider transactions for ENGN (enGene Therapeutics Inc.), covering filings from Nov 2, 2023 onwards. 1 of those are dated within the last 90 days.
Are ENGN insiders net buyers or net sellers?: Across the full Form 4 history for ENGN, 16 transactions (46%) were open-market purchases and 3 (9%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ENGN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
What sector is ENGN in?: enGene Therapeutics Inc. (ENGN) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $652.43M.

Methodology & sources

Every ENGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.